Hemic Or Immune System (e.g., Hematopoietic System, Bone Marrow Cells, Etc.) Patents (Class 424/577)
-
Patent number: 8637005Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: November 14, 2011Date of Patent: January 28, 2014Assignee: Amorcyte, Inc.Inventors: Andrew L. Pecora, Robert A. Preti
-
Publication number: 20140023723Abstract: Methods for producing compositions of decellularized extracellular matrix (DM) tissue culture are described. The compositions can be used for coating supports such as tissue culture substrates, osteogenic gels, and medical devices.Type: ApplicationFiled: April 16, 2012Publication date: January 23, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: J. Kent Leach, Martin Decaris, Archana Bhat
-
Patent number: 8604271Abstract: A mouse model in which human fetal thymus and human fetal bone fragments are transplanted into NSG mice, a method of producing the same, and a use thereof.Type: GrantFiled: September 7, 2011Date of Patent: December 10, 2013Assignee: Samsung Life Welfare FoundationInventors: Sung Joo Kim, Yun Shin Chung, Sung Yeon Joo, Bong Kim Choi, Jae Won Joh
-
Patent number: 8603486Abstract: Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 ?g.Type: GrantFiled: April 23, 2012Date of Patent: December 10, 2013Assignee: Protalex, Inc.Inventor: Paul Mann
-
Publication number: 20130323230Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.Type: ApplicationFiled: August 9, 2013Publication date: December 5, 2013Applicant: ParinGenix, Inc.Inventor: Stephen MARCUS
-
Publication number: 20130316014Abstract: One aspect of the present disclosure includes a method for predicting the prognosis of a subject with a myeloid malignancy. One step of the method includes obtaining a biological sample from the subject. Next, at least one mutation in a spliceosome-associated protein, or a polynucleotide encoding the spliceosome-associated protein that results in defective splicing can be detected in the biological sample. The presence of at least one mutation in the spliceosome-associated protein, or a polynucleotide encoding the spliceosome-associated protein, is indicative of the subject's prognosis.Type: ApplicationFiled: April 2, 2013Publication date: November 28, 2013Inventors: Jaroslaw P. Maciejewski, Hideki Makishima, Ramon Tiu, Valeria Visconte
-
Patent number: 8591956Abstract: A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.Type: GrantFiled: August 8, 2011Date of Patent: November 26, 2013Assignee: IRX Therapeutics, Inc.Inventors: John W. Hadden, Theresa L. Whiteside-Nimick, James E. Egan, Kathy L. Signorelli-Petrat, Harvey Brandwein
-
Patent number: 8586100Abstract: Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells.Type: GrantFiled: November 17, 2011Date of Patent: November 19, 2013Assignee: Children's Medical Center CorporationInventors: Alejandro Balazs, Richard Mulligan
-
Publication number: 20130287817Abstract: A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials.Type: ApplicationFiled: April 27, 2012Publication date: October 31, 2013Applicant: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Daniel A. Shimko
-
Patent number: 8541033Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.Type: GrantFiled: November 17, 2009Date of Patent: September 24, 2013Assignee: Central Institute for Experimental AnimalsInventors: Mamoru Ito, Kimio Kobayashi, Tatsutoshi Nakahata, Koichiro Tsuji, Sonoko Habu, Yoshio Koyanagi, Naoki Yamamoto, Kazuo Sugamura, Kiyoshi Ando, Tatsuji Nomura
-
Publication number: 20130236453Abstract: Methods and compositions for treating or preventing acute graft-versus-host disease (aGVHD) in a subject using miR-155 specific inhibitors are described.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: THE OHIO STATE UNIVERSITYInventors: Carlo M. Croce, Ramiro Garzon
-
Patent number: 8524283Abstract: A Method for obtaining amniotic mesenchymal tissue cells (AMTC) and/or chorionic mesenchymal tissue cells (CMTC) comprises a) isolating amniotic membrane and/or chorionic membrane from human placenta and/or separating amniotic and chorionic membrane, a) washing the membrane of step a) to remove contaminants b) cutting the membrane of step b) c) incubating the membrane fragments of step c) in a medium containing dispase for 5 to 15 minutes at 33 to 42° C. d) incubating the composition of step d) in a resting solution for 5 to 15 minute at room temperature e) repeating steps d) and e) 0 to 6 times f) if chorionic membrane is involved peeling the stromal layer from the trophoblastic layer of the chorionic membrane of step e or f) g) digesting the fragments obtained in step e), f), or g) respectively, with collagenase for 1 to 5 hours at 33 to 42° C. h) collecting AMTCs and/or CMTCs from the suspension obtained in step h).Type: GrantFiled: June 16, 2008Date of Patent: September 3, 2013Assignee: Centro di Ricerca E. Menni Fondazione Poliambulanza Istituto OspedalieroInventor: Ornella Parolini
-
Publication number: 20130195928Abstract: The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition.Type: ApplicationFiled: December 20, 2012Publication date: August 1, 2013Applicant: PIONEER SURGICAL TECHNOLOGYInventor: PIONEER SURGICAL TECHNOLOGY
-
Publication number: 20130171099Abstract: A method for suppressing T cell activation which comprises contacting a cell population comprising T cells in vitro or ex viva with an effective amount of STRO-1+ cells and/or soluble factors derived therefrom to suppress cell activation.Type: ApplicationFiled: July 4, 2011Publication date: July 4, 2013Applicant: MESOBLAST, INC.Inventors: Silviu Itescu, Michael David Schuster
-
Patent number: 8465773Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.Type: GrantFiled: May 15, 2012Date of Patent: June 18, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Syed Hossainy, Michael Ngo, Mikael Trollsas, John Stankus, Gene Michal
-
Patent number: 8465772Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.Type: GrantFiled: May 15, 2012Date of Patent: June 18, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Syed Hossainy, Michael Ngo, Mikael Trollsas, John Stankus, Gene Michal
-
Publication number: 20130136799Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.Type: ApplicationFiled: February 11, 2013Publication date: May 30, 2013Applicant: Sequenta, Inc.Inventor: Malek Faham
-
Patent number: 8440199Abstract: The current invention provides a method for mobilizing endothelial progenitor cells (EPC) and/or mesenchymal stem cells (MSC) in a patient, wherein the method comprises the steps of (i) administering a vascular endothelial growth factor receptor (VEGFR) agonist to the patient; and (ii) administering an antagonist of CXCR4 to the patient. Also provided are uses of EPC and MSC harvested using the methods of the invention.Type: GrantFiled: December 12, 2008Date of Patent: May 14, 2013Assignee: Imperial Innovations LimitedInventors: Sara Margaret Rankin, Simon Charles Pitchford
-
Patent number: 8431162Abstract: The presently disclosed subject matter provides an isolated subpopulation of bone marrow-derived adherent stem cells that are purified from bone marrow-derived adherent cells. Also provided are methods for isolating the subpopulation of bone marrow-derived adherent stem cells from bone marrow-derived adherent cells and for using the isolated subpopulation of bone marrow-derived adherent stem cells for treating tissue and/or organ damage in a subject.Type: GrantFiled: October 30, 2008Date of Patent: April 30, 2013Assignee: University of Louisville Research Foundation, Inc.Inventors: Ewa K. Zuba-Surma, Buddhadeb Dawn, Ahmed Abdel-Latif, Roberto Bolli
-
Patent number: 8388977Abstract: The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.Type: GrantFiled: June 21, 2012Date of Patent: March 5, 2013Assignee: Purdue Research FoundationInventors: Philip S Low, Mary Jo Turk
-
Publication number: 20130052272Abstract: The present invention concerns pharmaceutical compositions and methods for treating proliferative diseases, e.g. cancer using intracellular and extracellular extracts.Type: ApplicationFiled: February 10, 2011Publication date: February 28, 2013Inventor: Shahar Cohen
-
Patent number: 8383099Abstract: The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted.Type: GrantFiled: August 26, 2010Date of Patent: February 26, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark E. Dudley, Steven A. Rosenberg
-
Publication number: 20130022661Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.Type: ApplicationFiled: July 21, 2011Publication date: January 24, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Patent number: 8343485Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: December 6, 2011Date of Patent: January 1, 2013Assignee: Amorcyte, Inc.Inventors: Andrew L. Pecora, Robert A. Preti
-
Publication number: 20120321723Abstract: The invention is in the field of therapeutic treatment of tumours. The inventors have found that microvesicles derived from adult stem cells exert a remarkable anti-tumour effect when administered to a patient affected by a tumour disease. Preferred microvesicles are derived from a bone marrow-mesenchymal stem cell, a glomerular mesenchymal stem cell or a non-oval liver stem cell.Type: ApplicationFiled: February 28, 2011Publication date: December 20, 2012Applicant: FRESENIUS MEDICAL CARE DEUTSCHLAND G.M.B.H.Inventors: Stefania Bruno, Maria Herrera Sanchez, Valentina Fonsato, Giovanni Camussi, Ciro Tetta
-
Publication number: 20120315259Abstract: A method and composition for treating dermatological conditions and improving skin condition and helping hair to grow or thicken involves removing extracts including beneficial secretions from mesenchymal stem cells or other cells with regenerative properties to use itself or components thereof alone or with other skin or hair care reagents as a topical ointment or formula to apply to the skin or hair topically for therapeutic and cosmetic purposes.Type: ApplicationFiled: February 1, 2011Publication date: December 13, 2012Inventor: Hyman Friedlander
-
Patent number: 8313742Abstract: This invention relates to a musculoskeletogenic MSG graft composite made from whole bone marrow aspirate BMA having native levels of musculoskeletal progenitor cells MSPCs, comprising: a) a suspension of fractionated BMA comprising: i) MSPCs present at a level greater than their native level in whole BMA, and ii) red blood cells RBCs present at a level less than their native level in whole BMA, and b) a porous sterile matrix having an average pore size of at least 20 ?m.Type: GrantFiled: March 29, 2002Date of Patent: November 20, 2012Assignee: DePuy AcroMed, Inc.Inventors: Sudhakar Kadiyala, Scott P. Bruder
-
Patent number: 8309095Abstract: The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells.Type: GrantFiled: April 29, 2011Date of Patent: November 13, 2012Assignee: The General Hospital CorporationInventors: David T. Scadden, Laura M. Calvi, Gregor Adams, Henry M. Kronenberg
-
Patent number: 8287857Abstract: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.Type: GrantFiled: July 8, 2011Date of Patent: October 16, 2012Assignee: The United States of America, as represented by the Secretary, Deparment of Health and Human ServicesInventors: Mark E. Dudley, Steven A. Rosenberg, John R. Wunderlich
-
Publication number: 20120225056Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.Type: ApplicationFiled: November 10, 2009Publication date: September 6, 2012Applicant: Alexion Pharmaceuticals, Inc.Inventors: Russell P. Rother, Camille Bedrosian, Stephen P. Squinto, Leonard Bell
-
Patent number: 8252280Abstract: The present invention relates to methods of increasing function and/or mass in damaged striated muscle tissue of interest (e.g., cardiac or muscle tissue) by providing of a population of multipotent adult progenitor cells (“MAPCs”), which effectively generate new striated muscle over time.Type: GrantFiled: May 11, 2011Date of Patent: August 28, 2012Assignee: Regents of the University of MinnesotaInventors: Catherine M. Verfaillie, Robert Gallegos, Michael Jerosch-Herold
-
Publication number: 20120141433Abstract: The invention provides compositions of vaporized stem cell derivatives and methods for their use and manufacture in the treatment of skin conditions and other therapeutic applications. Stem cell derivatives comprising vaporized stem cells, stem cell factors and/or stem cell microvesicles are disclosed and contemplated as being within the scope of the invention. The invention finds use in medical, rejuvenative and cosmetic applications.Type: ApplicationFiled: October 3, 2011Publication date: June 7, 2012Inventors: Nikolai Tankovich, Yuri Kudinov
-
Patent number: 8192760Abstract: Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications.Type: GrantFiled: December 4, 2006Date of Patent: June 5, 2012Assignee: Abbott Cardiovascular Systems Inc.Inventors: Syed Hossainy, Michael Ngo, Mikael Trollsas, John Stankus, Gene Michal
-
Publication number: 20120121720Abstract: This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of ?2 adrenergic receptors or need for increased 132 adrenergic receptor activity.Type: ApplicationFiled: March 31, 2010Publication date: May 17, 2012Inventors: Jonathan S. Stamler, Liang Xie
-
Patent number: 8173129Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.Type: GrantFiled: December 7, 2009Date of Patent: May 8, 2012Assignee: The General Hospital CoporationInventor: Denise Faustman
-
Patent number: 8168189Abstract: Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 ?g.Type: GrantFiled: September 14, 2010Date of Patent: May 1, 2012Assignee: Protalex, Inc.Inventor: Paul Mann
-
Patent number: 8158118Abstract: A method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two color FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.Type: GrantFiled: June 29, 2005Date of Patent: April 17, 2012Assignee: Angioblast Systems, Inc.Inventors: Paul Simmons, Andrew Zannettino, Stan Gronthos
-
Publication number: 20120089084Abstract: A plasma coating device for treating a wound comprises a plasma chamber having: one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. An aerosol delivery system is operable to introduce a bioresorbable material as an aerosol into the plasma, to produce a coating on the wound surface.Type: ApplicationFiled: June 15, 2010Publication date: April 12, 2012Inventors: Joe O'Keeffe, Peter Dobbyn, John O'Donoghus, Liam O'Neil
-
Publication number: 20120052045Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.Type: ApplicationFiled: August 25, 2011Publication date: March 1, 2012Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp
-
Publication number: 20120016489Abstract: Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a2) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.Type: ApplicationFiled: July 16, 2010Publication date: January 19, 2012Applicant: EBI, LLCInventor: Bradford J. COALE
-
Publication number: 20120003188Abstract: The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: May 27, 2011Publication date: January 5, 2012Applicant: Garnet Biotherapeutics, Inc.Inventors: Gene KOPEN, Vanessa RAGAGLIA, Candace BRAYFIELD
-
Patent number: 8088370Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of cells having chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: March 10, 2009Date of Patent: January 3, 2012Assignee: Amorcyte, Inc.Inventors: Andrew Pecora, Robert Preti
-
Patent number: 8084057Abstract: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osteoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked ?-gal epitopes for induction of recruitment of macrophages localized within or surrounding damaged tissue. The recruited macrophages and stem cells promote the repair and regeneration of the treated injured tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects. In some embodiments, the present invention provides treatments for injured tissues such as brain, peripheral nerve, muscle, cartilage, bone, gastrointestinal tract and dysfunctional endocrine tissues.Type: GrantFiled: August 17, 2009Date of Patent: December 27, 2011Assignee: University of MassachusettsInventor: Uri Galili
-
Publication number: 20110305673Abstract: The invention features compositions comprising mesenchymal stem cells or multipotent stromal cells, agents secreted by such cells in culture, and methods featuring such cells for the repair or regeneration of a damaged tissue or organ. The present invention is based, at least in part, on the discovery that agents secreted by bone marrow mesenchymal stem cells or multipotent stromal cells (MSCs) were useful for the treatment or prevention of tissue damage related to ischemic injury (e.g., cerebral or cardiac ischemia).Type: ApplicationFiled: November 12, 2009Publication date: December 15, 2011Applicant: The University of Vermont and State Agriculture CollegeInventor: Jeffrey Spees
-
Patent number: 8075921Abstract: Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.Type: GrantFiled: March 30, 2010Date of Patent: December 13, 2011Assignees: The United States of America as represented by the Secretary of the Deparment of Health and Human Services, The Trustees of the University of PennsylvaniaInventors: Daniel H. Fowler, Unsu Jung, Ronald E. Gress, Bruce Levine, Carl June
-
Patent number: 8062675Abstract: A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.Type: GrantFiled: February 17, 2010Date of Patent: November 22, 2011Assignee: Angioblast Systems, Inc.Inventors: Stan Gronthos, Andrew Zannettino, Paul Simmons
-
Patent number: 8057826Abstract: The present invention provides isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), which simultaneously express a plurality of genes that are markers for multiple cell lineages, wherein the multiple cell lineages comprise at least four different mesenchymal cell lineages (e.g., adipocyte, osteoblast, fibroblast, and muscle cell) and wherein each of the markers is specific for a single cell lineage. The present invention also method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease.Type: GrantFiled: May 19, 2008Date of Patent: November 15, 2011Assignee: University of South FloridaInventor: Beerelli Seshi
-
Patent number: 8034334Abstract: A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.Type: GrantFiled: September 5, 2003Date of Patent: October 11, 2011Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Mark E Dudley, Steven A Rosenberg, John R Wunderlich
-
Patent number: 8021693Abstract: The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type.Type: GrantFiled: August 28, 2009Date of Patent: September 20, 2011Assignee: The General Hospital CorporationInventor: Denise L. Faustman
-
Patent number: RE43467Abstract: The present invention features a novel combination therapy useful in the treatment of autoimmune disease that increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system.Type: GrantFiled: October 25, 2010Date of Patent: June 12, 2012Assignee: The General Hospital CorporationInventor: Denise Faustman